Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity

Wang, Guiying; Wu, Peng; Qiu, Yan; Dong, Xin; Wang, Yingbin; Chi, Yanjun; Zhang, Fengjuan; Li, Yinyu; Zhang, Jimin; Zhen, Huang; Du, Xifeng; Du, Zhiqiang

doi:10.20945/2359-3997000000388

Cited by 7 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dosages administered to study participants were carefully balanced to achieve both body weight loss efficacy and tolerability. [14][15][16] The effects of beinaglutide treatment were evaluated in patients with a BMI of 24-27.9 kg/m 2 and of 28 kg/m 2 or higher, respectively, as indicative of overweight and obesity criteria in Chinese guidelines. 19 Beinaglutide was superior to placebo with regard to the two co-primary endpoints; moreover, the mean body weight reduction was sustained during the 12-week post-treatment observation period.…”

Section: Discussionmentioning

confidence: 99%

“…In this study, beinaglutide was administered at dosages used for diabetes indications, without the need for higher doses for body weight loss. The dosages administered to study participants were carefully balanced to achieve both body weight loss efficacy and tolerability 14–16 . The effects of beinaglutide treatment were evaluated in patients with a BMI of 24‐27.9 kg/m 2 and of 28 kg/m 2 or higher, respectively, as indicative of overweight and obesity criteria in Chinese guidelines 19 .…”

Section: Discussionmentioning

confidence: 99%

“…[10][11][12] Beinaglutide lowers HbA1c and body weight in patients with T2D and is being recommended by Chinese treatment guidelines as routine clinical practice. 13 The results of small-scale studies suggest that beinaglutide treatment for 12 weeks reduced the body weight of patients with overweight or obesity with 14,15 or without 16 co-morbid diabetes by 5%-10%. Real-world safety surveillance showed that nausea, dizziness and appetite loss were the most frequent adverse events (AEs) in 72 500 patients with T2D treated with beinaglutide.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study

Chen,

Shan

et al. 2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimTo investigate the efficacy and safety of beinaglutide as an adjunct to lifestyle intervention among non‐diabetic Chinese individuals with overweight or obesity.MethodsThis multicentre, randomized, double‐blind, placebo‐controlled trial (ChiCTR1900023428) included 427 Chinese adults with a body mass index of 28 kg/m2 or higher (obesity) or 24‐27.9 kg/m2 (overweight) with weight‐related complications. Patients were randomized in a 2:1 ratio to receive 0.2 mg of beinaglutide (subcutaneous) thrice daily or placebo for 16 weeks. Co‐primary endpoints were body weight change and the proportion of patients with a weight reduction of 5% or more.ResultsMean body weight change from baseline to week 16 was −6.0% and −2.4% in the beinaglutide (n = 282) and placebo (n = 138) groups, respectively; the mixed model repeated measures difference was −3.6% (95% confidence interval: −4.6% to −2.6%; P < .0001). At week 16, more beinaglutide‐treated patients achieved a weight reduction of 5% or more (58.2% vs. 25.4% [placebo], odds ratio: 4.4; P < .0001) and of 10% or more (21.3% vs. 5.1% [placebo], odds ratio: 5.5; P < .0001). Beinaglutide also resulted in greater waist circumference reduction (difference: −1.81 cm; P < .01). The weight regain rate 12 weeks after beinaglutide treatment was 0.78%. Nausea (transient and mild‐to‐moderate) was the most common adverse event in the beinaglutide group (49.3% vs. 7.1% [placebo]). More patients receiving beinaglutide discontinued treatment because of adverse events (5.9% vs. 0.7% [placebo]). Pancreatitis or an increased resting heart rate was not observed in the beinaglutide group.ConclusionBeinaglutide combined with lifestyle intervention resulted in significant and clinically meaningful weight reduction with good tolerance in non‐diabetic Chinese individuals with overweight or obesity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study

Chen,

Shan

et al. 2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…19 It also manifested a favorable effect on weight loss. 20 The use of beinaglutide in obese nondiabetic patients showed that its use was beneficial for weight loss, particularly pertaining to visceral fat. 20,21 Beinaglutide is also able to improve vascular endothelial function.…”

Section: Introductionmentioning

confidence: 99%

“…Compared with sulfonylureas, beinaglutide provided similar reductions in HbA1c but lowered the incidence of hypoglycemia 19 . It also manifested a favorable effect on weight loss 20 . The use of beinaglutide in obese nondiabetic patients showed that its use was beneficial for weight loss, particularly pertaining to visceral fat 20,21 .…”

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open‐label, randomized trial

Liu,

Yang,

Liu

et al. 2023

Journal of Diabetes

View full text Add to dashboard Cite

BackgroundTo compare glycemic control in Chinese patients with type 2 diabetes mellitus (T2DM) whose blood glucose levels were inadequately controlled with oral antidiabetic drugs after beinaglutide alone or combined with insulin glargine (IGlar).MethodsIn this 16‐week multicenter, randomized clinical trial, 68 participants randomly received beinaglutide or IGlar for 8 weeks, then the two drugs in combination for 8 weeks. The primary outcomes were the proportion of individuals achieving their glycemic target and the change in glucose variability as measured with a continuous glucose monitoring system from baseline to 8 and 16 weeks.ResultsBoth the beinaglutide and IGlar groups showed increased proportions achieving their glycemic target at 8 weeks, and the combination augmented the proportion reaching the glycated hemoglobin target from 25.42% at 8 weeks to 40.68% at 16 weeks. The beinaglutide group showed a significant reduction in body weight, body mass index, waist circumference, and systolic blood pressure. Beinaglutide elevated high‐density lipoprotein cholesterol by 0.08 mmol/L (95% confidence interval [CI], 0.00–0.16), and diminished low‐density lipoprotein cholesterol by 0.21 mmol/L (95% CI, 0.05–0.48), whereas IGlar showed no effect. Though IGlar was more efficient in lowering fasting plasma glucose than beinaglutide at comparable efficacies (to −1.57 mmol/L [95% CI, −2.60 to −0.54]), this difference was abolished in patients whose fasting C‐peptide was ≥0.9 ng/mL.ConclusionBeinaglutide exhibited a favorable hypoglycemic effect on patients with T2DM, and in combination with IGlar, glucose level was further decreased. Low fasting C‐peptide in patients may reduce the glycemic response to beinaglutide therapy. We recommend that C‐peptide levels be evaluated when using or switching to the novel glucagon‐like peptide‐1 receptor agonists beinaglutide.Trial RegistrationClinicalTrials.gov: NCT03829891.

show abstract

Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications

Zhang

Zhao

Chen

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Sarcopenia, characterized by loss of skeletal muscle mass, quality, and strength, has become a common hallmark of ageing and many chronic diseases. Diabetes mellitus patients have a higher prevalence of sarcopenia, which greatly aggravates the metabolic disturbance and compromises treatment response. Preclinical and clinical studies have shown differential impacts of anti‐diabetic drugs on skeletal muscle mass, strength, and performance, highlighting the importance of rational therapeutic regimen from the perspective of sarcopenia risk. In this review, we provide an update on the regulation of muscle mass and quality by major anti‐diabetic drugs, focusing primarily on emerging data from clinical studies. We also discuss the underlying mechanisms and clinical implications for optimal selection of anti‐diabetic drugs to reduce the risk of sarcopenia. In view of the lifelong use of anti‐diabetic drugs, we propose that a better understanding of the sarcopenia risk and interventional strategies is worthy of attention in future studies.

show abstract

Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity

Cited by 7 publications

References 29 publications

Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study

Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study

The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open‐label, randomized trial

Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications

Contact Info

Product

Resources

About